Developments in the Treatment of Carcinoid Syndrome &Ndash; Impact of Telotristat

Therapeutics and Clinical Risk Management
doi 10.2147/tcrm.s126143
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Spotlight on Telotristat Ethyl for the Treatment of Carcinoid Syndrome Diarrhea: Patient Selection and Reported Outcomes

Cancer Management and Research
Oncology
2019English

Parachlorophenylalanine Treatment in Carcinoid Syndrome.

BMJ
1970English

New Developments in the Treatment of Neuroendocrine Tumours – RADIANT-4, NETTER-1 and Telotristat Etiprate

European Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2016English

Surgical Approaches and Drug Treatment in the Carcinoid Syndrome.

BMJ
1978English

Update and Developments in the Treatment of Glioblastoma Multiforme &Ndash; Focus on Bevacizumab

Pharmacogenomics and Personalized Medicine
Molecular MedicinePharmacology
2010English

New Developments in the Treatment of Primary Biliary Cholangitis &Ndash; Role of Obeticholic Acid

Therapeutics and Clinical Risk Management
2017English

Carcinoid Syndrome Due to Carcinoid Tumour of the Ovary

BMJ
1964English

Identification of Targets and New Developments in the Treatment of Multiple Sclerosis &Ndash; Focus on Cladribine

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2010English

The Vasculocardiac Syndrome of Metastatic Carcinoid

Archives of Internal Medicine
1959English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy